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Supplemental Figures 
 
Supplemental Figure S1.  Renal scarring is evident at day 210 (week 30) after induction of EAV. 
WKY rats were immunised with hMPO or HSA and sacrificed at day 56 (week 8) or day 210 (week 
30). The degree of renal scarring was assessed by staining tissue with picrosirius red and PAMS. (A) 
Picrosirius red staining was quantified by blinded image analysis. The median fraction of kidney 
tissue staining red was higher in animals analysed at day 210 than at the peak of acute 
glomerulonephritis at day 56. Data are presented as the median and IQR. (B, D) Representative 
images of picrosirius red stained kidney after (B) 210 days and (D) 8 weeks (x4). (C) Representative 
kidney section stained with PAMS in a rat with EAV sacrificed at day 210 (x20). Fibrous tissue is 
stained black.  
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Supplemental Figure S2. Binned 1D NMR spectra of rat urine at point of peak disease (day 56) and 
following induction of relapse with MPO/LPS (day 210). (A) PLS-DA weights plot for LV 1 showing 
key contributing NMR peaks to separation between HSA and MPO treated rats at day 56, with 
positive values indicating metabolites raised in MPO treated animals. Treated rats had increased 
TMAO, 2-oxoglutarate, citrate, betaine and DMG. (B) PLS-R rank plot of urinary NMR peaks at day 56 
found to be positively or negatively correlated with histological glomerular damage score. Predictive 
peaks are labelled, including TMAO, 2-oxoglutarate, succinate, betaine, citrate and maltose. (C) PLS-
DA weights plot for LV 1 showing key contributing NMR peaks to separation between MPO re-
stimulated and saline treated rats at day 210, with positive values indicating metabolites raised in 
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MPO treated animals. Treated rats had increased citrate, 2-oxoglutarate, TMAO, carnosine and beta-
alanine. (D) PLS-R rank plot of urinary NMR peaks at day 210 found to be positively or negatively 
correlated with histological glomerular damage score. Predictive peaks are labelled, including TMAO, 
dimethylamine, 2-oxoglutarate, maltose, citrate and betaine. 
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Supplemental Figure S3. Comparison of the effect of treatment on urine myo-inositol:citrate ratio 
in the urine of patients with active renal vasculitis and those in remission. CYC=Cyclophosphamide; 
RTX=Rituximab; +/- implies that the group contains patients both receiving and not receiving 
corticosteroid therapy.   
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Supplemental Tables 
 
Predictor Sum of Squares df F Sig. 
Haematuria 22.77 1 35.511 0 
DMG 0.10 1 5.915 0.025 
TMAO 1.89 1 5.651 0.028 
ACR 48389 1 4.78 0.042 
2-oxoglutarate 0.31 1 2.808 0.11 
Citrate 0.53 1 1.592 0.222 
Succinate 0.01 1 0.661 0.426 
Supplemental Table S1. ANOVA of key day 56 factors discriminating between MPO and HSA 
immunised rats. The existing markers (haematuria and ACR) are both significant (p<0.001 and 
p<0.05 respectively). Novel metabolite biomarkers DMG and TMAO are also significant 
discriminators at this time point (p<0.05). 
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Predictor Sum of Squares df F Sig. 
2-oxoglutarate 0.09 1 7.11 0.024 
Citrate 0.12 1 1.693 0.222 
TMAO 0.04 1 0.502 0.495 
ACR 13348.41 1 0.475 0.506 
Succinate 0.002 1 0.255 0.625 
Haematuria 0.01 1 0.012 0.913 
DMG 0 1 0 0.989 
Supplemental Table S2. ANOVA of key day 210 factors discriminating between animals relapsed 
with MPO and vehicle.  The existing markers (haematuria and ACR) were poor predictors at this 
time point (both p>0.05). Of the putative urine metabolite biomarkers only 2-oxoglutarate was a 
significant predictor in this analysis. 
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Vasculitis 
patients 
Disease 
Controls 
Healthy 
Controls 
p-value 
n 143 23 45  
Age (median, range) 63.3 (21-90) 62.2 (16-87) 53.9 (20-76) 0.002 
Male, n (%) 76 (53.1) 11 (47.8) 15 (30.0) 0.001 
Diagnosis, n (%)     
GPA 82 (57.3) NA NA  
MPA 44 (30.8) NA NA  
EGPA 10 (6.9) NA NA  
Anti-GBM disease 3 (2.0) NA NA  
Double Positive#  4 (2.8) NA NA  
ANCA specificity, n (%)     
Proteinase-3 81 (60) NA NA  
Myeloperoxidase 54 (40) NA NA  
Disease Characteristics, n (%)     
Active (renal) 28 (19.6) NA NA  
Active (extra-renal) 11 (7.7) NA NA  
Remission 104 (72.8) NA NA  
Kidney function, n (%)    0.5* 
eGFR <30 25 (17.5) 3 (13.0)   
eGFR 30-60 44 (30.8) 10 (43.5)   
eGFR >60 74 (51.8) 10 (43.5) 45 (100)  
Dialysis 10 (6.9) 0 (0) 0 (0)  
Immunosuppressive treatment, n%    
Corticosteroids 88 (61.5) 4 (17.4) 0  
Cyclophosphamide 10 (7.0) 0 (0) 0  
Rituximab 6 (4.2) 0 (0) 0  
Other 56 (39.2)~ 4 (17.4) 0  
None 42 (29.4) 17 (73.9) 0  
Supplemental Table S3. Details of cases used in human LC-MS analysis. *Comparing disease 
controls and vasculitis cases. #Double positive for both ANCA and anti-GBM. ~Azathioprine, 
methotrexate or mycophenolate mofetil, NA = Not applicable 
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 B Std OR Bias S.E. Sig 95 C.I. 
Citric acid -39.65 0.07 -9.704 32.382 0.037 -9.21 -0.87 
Myo-Inositol 6039 9.24 1263.52 3322.589 0.001 1.44 5.72 
Model constant -0.046 0.05 0.184 1.157 0.973 -8.92 -1.72 
Supplemental table S4. Binary logistic model of metabolite predictors with bootstrapping. The 
established model was bootstrapped (997 samples) to improve estimates of model accuracy. 
Bootstrapping confirmed predictors that were significantly altered in active renal vasculitis 
compared to cases in remission.  
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Compound Precursor 
ion (m/z) 
Product 
ion 
(m/z) 
Dwell 
Time 
(ms) 
Collision 
Energy 
(V) 
Cell 
Accelerator 
(V) 
Polarity 
N-
Phenylacetylglycine 
194.1 91.05 20 15 2 + 
N-
Phenylacetylglycine 
194.1 76.04 20 15 2 + 
Betaine 118.09 59.07 20 25 2 + 
Betaine 118.09 58.06 20 25 2 + 
Creatinine 114.1 86.1 20 10 2 + 
Creatinine 114.1 72 20 10 2 + 
Creatinine 114.1 44.1 20 40 2 + 
Dimethylglycine 104.07 58.06 20 15 2 + 
Dimethylglycine 104.07 42.03 20 15 2 + 
TMAO 76.1 58.1 20 20 2 + 
Maltose 341.1 221.07 20 15 2 - 
Maltose 341.1 161.01 20 5 2 - 
Maltose 341.1 101.02 20 15 2 - 
Citric Acid 191.02 111 20 10 2 - 
Citric Acid 191.02 87 20 15 2 - 
Myo Inositol 179.06 161 20 10 2 - 
Myo Inositol 179.06 87 20 15 2 - 
Oxoglutaric Acid 145 101 20 10 2 - 
Oxoglutaric Acid 145 73 20 10 2 - 
Oxoglutaric Acid 145 57 20 10 2 - 
Glutaric Acid 131.03 113 20 10 2 - 
Glutaric Acid 131.03 87 20 10 2 - 
Succinate 117.02 99 20 10 2 - 
Succinate 117.02 73 20 10 2 - 
Glycolic Acid 75 75 20 0 2 - 
Glycolic Acid 75 57 20 3 2 - 
Supplemental Table S5. Collision energies used in LC-MS analysis.  
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